Bibliography
- Williams RJ. Discontinued drugs in 2012: oncology drugs. Expert Opin Investig Drugs 2013;22(12):1627-44
- Borden C and Dowlati A. Phase I trials of targeted anticancer drugs: a need to refoucus. Nature Rev Drug Discov 2012;11:889-90
- Cook D, Brown D, Alexander R, et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nature Rev Drug Discov 2014;6):419-31
- Morgan P, Van Der Graff P, Arrowsmith J, et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Disc Today 2012;17(9-10):419-24
- Cohen RB, Aamdal S, Nyakas M, et al. A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies. Eur J Cancer 2013;49(7):1521-5129
- Mateo J, Ong M, Tan DSP, et al. Appraising iniparib, the PARP inhibitor that never was-what must we learn? Nat Rev Clin Oncol 2013;10(12):688-96
- Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Rev Drug Discov 2010;3):203-14
- Arrowsmith A and Miller P. Phase II and phase III attrition rates 2011-2012. Nature Rev Drug Discov 2013;12(8):569
- DiMasi JA. Causes of clinical failures vary widely by therapeutic class, phase of study. Tufts Impact Report 2013;15:5
- Bradley E. Incorporating biomarkers into clinical trial designs: points to consider. Nature Biotech 2012;7):596-9
- Available from: https://clinicaltrials.gov
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Rev Drug Disc 2004;3(8):711-15
- Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nature Biotech 2014;32(1):40-51
- Rubin EH, Gilland DG. Drug development and clinical trials – the path to an approved cancer drug. Nat Rev Clin Oncol 2012;9(4):215-22
- Available from: www.scripintelligence.com/home/Is-the-cost-of-anticancer-therapy-justified-350983
- Ringel M, Tollman P, Hersch G, Schulze U. Does size matter in R&D productivity? If not, what does? Nature Rev Drug Discov 2013;12(12):901-2
- Pharma 2020 – From vision to decision. Available from: www.pwc.co.uk/pharmaceuticals-life-sciences/publications/from-vision-to-decision-pharma-2020.jhtml